Guidelines from the American Academy of Dermatology and National Psoriasis Foundation (AAD-NPF) recommend that anti-il-17 monoclonal antibodies can be selected for HIV patients who are receiving antiretroviral therapy and have a controlled viral load [10, 11]. This evidence concerns the gene IL17A and psoriasis.